Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
Status:
Completed
Trial end date:
2010-01-26
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering
activity of MK-8245 in participants with type 2 diabetes. The primary hypothesis of the study
is that after 4 weeks of treatment, MK-8245 produces a greater reduction in 24 hour weighted
mean glucose (WMG) from baseline than placebo.